ReviewHeart failure reviews2002
Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective.
Review in Heart failure reviews, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 98 citations in OpenAlex.
- Skeletal Muscle Metabolism: Origin or Prognostic Factor for Amyotrophic Lateral Sclerosis (ALS) Development?Cells · 2021Review
- Cardiac foetal reprogramming: a tool to exploit novel treatment targets for the failing heart.Journal of internal medicine · 2020Review
- Can blood glucose value really be referred to as a metabolic parameter?Reviews in endocrine & metabolic disorders · 2019Review
- Trimetazidine and Other Metabolic Modifiers.European cardiology · 2018Review
- Development of Dihydroxyphenyl Sulfonylisoindoline Derivatives as Liver-Targeting Pyruvate Dehydrogenase Kinase Inhibitors.Journal of medicinal chemistry · 2017Article
- Cardiac-Specific Deletion of the Pdha1 Gene Sensitizes Heart to Toxicological Actions of Ischemic Stress.Toxicological sciences : an official journal of the Society of Toxicology · 2016Article
- ADORA2b Signaling in Cardioprotection.Journal of nature and science · 2016Article
- Protective effect of tetramethylpyrazine on myocardial ischemia-reperfusion injury.Evidence-based complementary and alternative medicine : eCAM · 2014Review
- Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.Naunyn-Schmiedeberg's archives of pharmacology · 2013Article
- Metabonomic strategy to the evaluation of chinese medicine compound danshen dripping pills interfering myocardial ischemia in rats.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia.Nature medicine · 2012Article
- Modulating fatty acid oxidation in heart failure.Cardiovascular research · 2011Review
- Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study.Heart and vessels · 2009Article
- Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention strategy.Vascular health and risk management · 2009Review
- Metabolic modulation of myocardial ischemia.Current cardiology reports · 2006Review
- Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.Heart failure reviews · 2005Review
- Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion.The Biochemical journal · 2005Review
- Hibernation and congestive heart failure.Heart failure reviews · 2003Review
- Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.Indian heart journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article discusses pharmacological approaches to optimizing myocardial metabolism during ischemia. Fatty acids are the main fuel for the healthy heart, with a lesser contribution coming from the oxidation of glucose and lactate. Myocardial ischaemia dramatically alters fuel metabolism, causing an accelerated rate of glucose conversion to lactate and a switch from lactate uptake by the heart to lactate production. This causes a dramatic disruption in cell homeostasis (e.g. lactate accumulation and a decrease in pH and ATP). Paradoxically, moderately ischemic tissue (approximately 50% of normal flow) continues to derive most of its energy (50-70%) from the oxidation of fatty acids despite a high rate of lactate production. This ischaemia-induced disruption in cardiac metabolism can be minimized by metabolic agents that reduce fatty acid oxidation and increase the combustion of glucose and lactate, resulting in clinical benefit to the ischemic patient. Agents that inhibit fatty acid beta-oxidation, such as ranolazine and trimetazidine, have proven to be effective in the treatment of stable angina. Treatment of acute myocardial infarction patients with an infusion of the glucose-insulin-potassium, which results in suppression of myocardial fatty acid oxidation and greater glucose combustion, has proven effective in reducing mortality. These metabolic therapies are free of direct hemodynamic or chronotropic effects, and thus are well positioned for use alongside traditional agents such as beta-adrenergic receptor antagonists or calcium channel antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.